Final results of a phase I study of Y-90-ibritumomab-tiuxetan (Y-90-IT) in children with recurrent/refractory CD20 positive lymphoma: A COG phase I consortium study
Document Type
Journal Article
Publication Date
2006
Journal
Cancer Biotherapy and Radiopharmaceuticals
Volume
21
Issue
4
Inclusive Pages
394-395
APA Citation
Cairo, M., Cooney, E., Krailo, M., Belanger, R., & Perkins, S. (2006). Final results of a phase I study of Y-90-ibritumomab-tiuxetan (Y-90-IT) in children with recurrent/refractory CD20 positive lymphoma: A COG phase I consortium study. Cancer Biotherapy and Radiopharmaceuticals, 21 (4). Retrieved from https://hsrc.himmelfarb.gwu.edu/smhs_peds_facpubs/4482
COinS